Brief: ADC Therapeutics Announces Encouraging Interim Results From Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine Presented At The 16Th Annual International Conference On Malignant Lymphoma
22/06/2021 15:55
June 22 (Reuters) - ADC Therapeutics SA ADCT.N :
* ADC THERAPEUTICS ANNOUNCES ENCOURAGING INTERIM RESULTS
FROM
PIVOTAL PHASE 2 CLINICAL TRIAL OF CAMIDANLUMAB TESIRINE (CAMI)
PRESENTED AT THE 16TH ANNUAL INTERNATIONAL CONFERENCE ON
MALIGNANT LYMPHOMA
* ADC THERAPEUTICS SA - PHASE 2 SAFETY PROFILE, INCLUDING
INCIDENCE OF GBS, CONSISTENT WITH PHASE 1
Source text for Eikon: urn:newsml:reuters.com:*:nBw3VK90Va
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview